Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 989 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024

Migraine
NEJM 383:1866-1876, Ashina, M., 2020

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Reversible Cerebral Vasoconstriciton Syndrome
www.UptoDate.com, June, Singhal, A., 2019

Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017

Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015

Fungal Infections Associated with Contaminated Methylprednisolone Injections - Preliminary Report
NEJM 368:2495-2509, Kauffman, C.,et al, 2013

Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013

Neuro-Sweets Disease
Pract Neurol 12:126-130, Maxwel,G.,et al, 2012

Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010

A Systematic Review of Antiepilpetic Drug Initiation and Withdrawal
The Neurologist 15:122-131, Shih,J.J &Ochoa,J.G., 2009

Delirium in Older Persons
NEJM 354:1157-1165, Inouye,S.K., 2006

Chronic Inflammatory Demyelinating Polyneuropathy
NEJM 352:1343-1356, Koller,H.,et al, 2005

Tinnitus
NEJM 347:904-910, Lockwood,A.H.,et al, 2002

Protocol Violations in Community-Based rTPA Stroke Treatment Are Associated with Symptomatic Intracerebral Hemorrhage
Stroke 32:12-16, Lopez-Yunez,A.M.,et al, 2001

Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke
Arch Neurol 58:2009-2013, Grotta,J.C.,et al, 2001

Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke
JAMA 283:1145-1150,1189, Albers,G.W.,et al, 2000

Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke
JAMA 283:1151-1158,1189, Katzan,I.L.,et al, 2000

Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998

A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
NEJM 394:442-450, Ryan,S.J.,et al, 2026

Restless Legs Syndrome, A Review
JAMA 335:703-714, Winkelmen,J.W. & Wipper, B., 2026

Commonly Used Interventional Procedures for Non-Cancer Chronic Spine Pain: A Clinical Practice Guideline
BMJ 388:e079970, Busse,J.W.,et al, 2025

Severe Myotonic Crisis Resembling Malignant Hyperthermia
Neurol 104:e213497, Wadhwani,A.R.,et al, 2025

Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025

Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025

Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025

A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025

AAV9-Mediated Gene Therapy for Infantile-Onset Pompes Disease
NEJM 392:2438-2446, 2477, Ma,X.,et al, 2025

Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons with Dementia
Neurol 105: e213717, Zissimopoulos, J.,et al, 2025

Neuroimaging Findings in Children and Young Adults with Neurotoxicity after CAR T-Cell Therapy for B-Cell Malignancies
Neurol 105:e214086, McGuire,J.L.,et al, 2025

Angioedema Following Tenecteplase for Acute Ischemic Stroke
Stroke 55:e242-e244, Dellabella,A.,et al, 2024

Angioedema After Use of Recombinant Tissue-Type Plasminogen Activators in Stroke
Stroke 55:2193-2197, Hutten,E., 2024

Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024

Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024

Cerebral Venous Thrombosis in a Transgender Man Receiving Testosterone Therapy and Progestin Implant
AIM Clin Cases 4:e240196, Chen,D.R.,et al, 2024

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Phase 2 Trial of Difelikefalin in Notalgia Paresthetica
NEJM 388:511-517, Kin,B.S.,et al, 2023

Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023

New-Onset Diplopia and Headache in a Patient with Metastatic Breast Cancer
Neurol 100:927-931, Rizzo,S.A.,et al, 2023

Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023

Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023

Trial of Botulinum Toxin for Isolated or Essential Head Tremor
NEJM 389:1753-1765, Marques,A.,et al, 2023

Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023

Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022

Chorioretinopathy After Corticosteroid Treatment for Optic Neuritis
Neurol 96:e305-e306, Ling, J. and Micieli, J.A., 2021

Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021

Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021

Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021



Showing articles 0 to 50 of 989 Next >>